

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, April 19, 2023, 9 a.m. to 2:35 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Alex Park, Committee Chair
9:05 a.m.	Asthma and COPD Agents <ul style="list-style-type: none"> • Anticholinergics • Phosphodiesterase 4 Inhibitors • Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations • Long Acting Muscarinic Agents • Inhaled Corticosteroid Combinations • Inhaled Corticosteroids • Monoclonal Antibodies <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
9:40 a.m.	Corticosteroids <ul style="list-style-type: none"> • Glucocorticosteroids <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
9:45 a.m.	Hematopoietic Agents <ul style="list-style-type: none"> • Erythropoiesis-Stimulating Agents (ESAS) • Gaucher Disease • Granulocyte Colony-Stimulating Factors (G-CSF) • Sickle Cell Anemia <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
10:20 a.m.	Break (10 min)	All
10:30 a.m.	Immune Modulators <ul style="list-style-type: none"> • Thalidomide Analogues Oncology Agents <ul style="list-style-type: none"> • Alkylating Agents - Oral • Antineoplastics Misc - Oral • BCL-2 Inhibitors – Oral • Histone Deacetylase Inhibitors – Oral • Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral • Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral • Janus Associated Kinase (JAK) Inhibitors – Oral 	Umang Patel, Magellan Marissa Tabile, HCA

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • Proteasome Inhibitors – Oral • XPO1 Inhibitors – Oral • Antimetabolites – Oral • Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral • Imidazotetrazines – Oral • Antiestrogens – Oral • Estrogens-Antineoplastic – Oral • Nitrogen Mustards – Oral • Autologous Cellular Immunotherapy (CAR-T) • Mitotic Inhibitors – Oral • Nitrosoureas – Oral • Selective Retinoid X Receptor Agonists – Oral • Antiadrenals - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	
11:45 a.m.	Antihyperlipidemics <ul style="list-style-type: none"> • Adenosine Triphosphate-Citrate Lyase Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:50 a.m.	Bone Density Regulators <ul style="list-style-type: none"> • Selective Estrogen Receptor Modulators (SERMS) <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:55 a.m.	Cardiovascular Agents <ul style="list-style-type: none"> • Transthyretin Stabilizers <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
12:00 p.m.	Lunch (30 min)	All
12:30 p.m.	Endocrine and Metabolic Agents <ul style="list-style-type: none"> • Fabry Disease Agents – Oral • Homocystinuria Agents – Oral • Hyperammonemia Agents – Oral • Urea Cycle Disorder Agents – Oral • Vasopressin Receptor Antagonists – Oral • Hereditary Tyrosinemia Type 1 (HT-1) Agents - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan Marissa Tabile, HCA
12:45 p.m.	Neuromuscular Agents <ul style="list-style-type: none"> • Muscular Dystrophy Agents • Systemic Lupus Erythematosus Agents • Antimyasthenic/Cholinergic Agents <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan Marissa Tabile, HCA
1:15 p.m.	Gastrointestinal Agents <ul style="list-style-type: none"> • Short Bowel Syndrome <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Marissa Tabile, HCA
1:35 p.m.	Hematological Agents - Misc <ul style="list-style-type: none"> • Aminolevulinate Synthase 1-Directed siRNA <ul style="list-style-type: none"> ○ Stakeholder input* 	Marissa Tabile, HCA

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> ○ Motion 	
1:55 p.m.	Ophthalmic Agents <ul style="list-style-type: none"> ● Nerve Growth Factors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Marissa Tabile, HCA
2:15 p.m.	Vasopressors <ul style="list-style-type: none"> ● Misc - Oral <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Marissa Tabile, HCA
2:35 p.m.	Drug Utilization Review Board Adjourns	Alex Park, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.